Novartis AG (id:12977 NOVN)
87.68 CHF
Opening hours: 09:00 - 17:20 (Central European Standard Time: 12/24/2024 6:12:50 PM)
Exchange closed, opens in 14 hours 47 minutes
About Novartis AG
Market Capitalization 173.38B
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Headquarters (address) |
Lichtstrasse 35 Basel 4056 Switzerland |
| Phone | 41 61 324 1111 |
| Website | https://www.novartis.com |
| Employees | 76K |
| Sector | Healthcare |
| Industry | Drug Manufacturers General |
| Ticker | NOVN |
| Exchange | Swiss Stock Exchange |
| Currency | CHF |
| 52 week range | 83.63 - 102.72 |
| Market Capitalization | 173.38B |
| Dividend yield forward | 15.05 % |
| Dividend yield forward Switzerland (ID:153, base:162) | 12.89 % |
| P/E trailing | 16.94 |
| P/E forward | 14.03 |
| Price/Sale | 3.47 |
| Price/Book | 4.00 |
| Beta | 3.00 |
| EPS | 5.12 |
| EPS Switzerland (ID:153, base:188) | 28.46 |
Dividend growth streak
Novartis AG has raised their dividend 26.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Novartis AG has raised their dividend 15.05 years in a row. This is below the 42122.087500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Novartis AG has raised their dividend 2.75 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Novartis AG has raised their dividend 2.71 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Novartis AG has raised their dividend 3.36 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Novartis AG has raised their dividend 65.52 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Novartis AG years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry
Dividend growth streak
Novartis AG has raised their dividend 26.00 years in a row. This is above the 4.499729 year average in the 'Drug Manufacturers General' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: Novartis AG has raised their dividend 15.05 years in a row. This is below the 42122.087500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 3 Years
Compound Average Growth Rate 3 Years: Novartis AG has raised their dividend 2.75 years in a row. This is below the 23.957000 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 5 Years
Compound Average Growth Rate 5 Years: Novartis AG has raised their dividend 2.71 years in a row. This is below the 12.560500 year average in the 'Drug Manufacturers General' industry
Compound Average Growth Rate 10 Years
Compound Average Growth Rate 10 Years: Novartis AG has raised their dividend 3.36 years in a row. This is below the 10.207200 year average in the 'Drug Manufacturers General' industry
Payout Ratio
Payout Ratio: Novartis AG has raised their dividend 65.52 years in a row. This is below the 148.467900 year average in the 'Drug Manufacturers General' industry
Self funded year
Novartis AG years needed to self fund. This is below the 34.112811 year average in the 'Drug Manufacturers General' industry